Charles River Laboratories and The Tri-Insitutional Therapeutics Discovery Institute Announce Strategic
Partnership
Partnership Intends to Accelerate Translation of Discoveries into Novel Therapies for Patients
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership
agreement with The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI), intended to accelerate the development of
therapeutics that arise from discoveries made in Tri-I TDI’s academic labs.
Tri-I TDI is a cooperative endeavor of Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell
Medicine, with a focus on the early stages of compound and biologic agent development, as well as “proof of concept” studies that
determine which drug candidates can successfully alter the course of a disease.
“This partnership reinforces Charles River’s continued commitment to expedite the early-stage development of innovative
treatments and therapies for patients,” said Dr. Emily Hickey, Corporate Senior Vice President, Global Discovery Services, Charles
River. “Our new partnership will leverage Charles River’s drug discovery and safety assessment expertise with both Tri-I TDI’s
research strengths and the cutting-edge work of their member institutions’ scientific leaders.”
Through this partnership, Charles River will provide Tri-I TDI with discovery and safety assessment services to support a range
of projects that are at the frontier of science. The collaboration will enhance Tri-I TDI’s efforts to more effectively develop
therapeutics for unmet medical needs.
“Our partnership with Charles River opens up a new pathway to innovation for Tri-I TDI,” said Michael A. Foley, Chief Executive
Officer, Tri-I TDI. “Its decades of experience in drug discovery and safety assessment, combined with a robust portfolio of
services, will provide us with additional capabilities to rapidly advance our projects.”
About The Tri-Institutional Therapeutics Discovery Institute
The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI). Tri-I TDI is a partnership of three world-renowned
scientific and medical institutions — Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell
Medicine. A novel partnership of academic institutions, the Tri-I TDI links researchers in basic and clinical science with experts
in drug discovery from the biotech and pharmaceutical industries, with the goal of more efficiently translating discoveries into
therapies for disease. Launched in 2013 in New York City the Tri-I TDI focuses on the early stages of developing compounds and
biologic agents, and conducts “proof of concept” studies needed to demonstrate that drug candidates can successfully alter the
course of a disease. To learn more, visit www.tritdi.org.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies
and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees
are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and
safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services,
visit www.criver.com.
Charles River Laboratories International, Inc.
Investor Contact:
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media Contact:
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations
amy.cianciaruso@crl.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160922005165/en/